Pro Medicus Ltd (ASX: PME) experienced a dip in its share price on Monday morning, with its stock trading down by nearly 1% to $131.67 at the time of writing. This decline occurred despite the health imaging technology company announcing two significant contract renewals in the United States.
The broader market weakness, which saw the ASX 200 index fall by 3.2%, appears to have overshadowed the positive news for Pro Medicus. Had the market been performing more strongly, it’s likely the company’s shares would have seen a notable increase.
Major Contract Renewals Boost Pro Medicus’s Future Prospects
Pro Medicus’s wholly-owned US subsidiary, Visage Imaging, has successfully secured two five-year contract renewals. These agreements carry a combined minimum value of $40 million, underscoring the company’s strong standing in the US healthcare market.
The most substantial of these renewals is with MedStar Health, a prominent healthcare system operating across the Maryland and Washington, D.C. metropolitan area. This deal alone is valued at $31 million. Under the terms of this renewed agreement, MedStar Health will continue to utilise the comprehensive suite of Visage 7 modules, which includes the Visage 7 Viewer, Open Archive, and Worklist products. Crucially, the renewal will also see the integration of Pro Medicus’s Visage 7 Cardiology imaging module, indicating an expansion of services within this key client relationship.
In addition to the MedStar Health contract, Pro Medicus has also finalised a $9 million, five-year renewal with Zwanger-Pesiri. This client is a significant private outpatient radiology provider based on Long Island, in the United States.
A key highlight of both these agreements is their transaction-based structure. This means the total value of the contracts could potentially exceed the stated minimums, depending on the volume of usage. Furthermore, the company has indicated that these renewals were negotiated at higher per-transaction fees, suggesting improved revenue generation per service provided.
Management’s Optimism on Strategic Growth
Dr. Sam Hupert, the CEO of Pro Medicus, expressed his satisfaction with the contract renewals. He particularly emphasised the significance of the MedStar Health agreement, noting that it represented the company’s first client to be fully deployed on the cloud.
“The Medstar renewal is notable in that MedStar was our first fully cloud deployed customer and has grown considerably since their initial go live,” stated Dr. Hupert. He further added, “Renewing this contract, and adding the Cardiology product, confirms our belief that we have the preeminent and most scalable enterprise imaging solution, that is fully cloud native.” This sentiment highlights the company’s confidence in its cloud-native technology and its ability to scale with growing healthcare systems.
Dr. Hupert also commented on the Zwanger-Pesiri renewal, underscoring the long-standing and successful relationship between the two entities. “We are very pleased to have played such a key role in Zwanger Pesiri’s growth over the past 10 years,” he remarked. He continued, “Zwanger-Pesiri have now renewed for a third contract term, re-iterating our belief that our solution provides the best return on investment of any system in the market from both a financial and clinical perspective.” This long-term partnership and repeated renewal signify strong client satisfaction and the perceived value proposition of Pro Medicus’s offerings.
The securing of these new contract renewals, coupled with the advantageous pricing structures and the expansion of product adoption by existing clients, presents a positive outlook for Pro Medicus. Despite the short-term market reaction, the underlying fundamentals of these deals point towards continued growth and profitability for the health imaging technology firm.
